Could a painkiller stop the cough that Won't quit in lung fibrosis?
NCT ID NCT07671911
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether an extended-release form of nalbuphine, a pain medication, can safely reduce chronic coughing in people with idiopathic pulmonary fibrosis (IPF), a lung scarring disease. About 306 adults with IPF and a cough lasting at least 8 weeks will receive either the drug or a placebo for 26 weeks. The main goal is to see if the drug lowers the number of coughs per day.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nalbuphine extended-release tablets
What this could lead to
If it works, this could provide a new treatment option to ease chronic coughing in people with idiopathic pulmonary fibrosis, improving their quality of life.
What could go wrong
This is a Phase 3 trial, but it's still experimental. The drug may not reduce cough significantly, and side effects like drowsiness or dizziness are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••